% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Dafsari:851195,
author = {Dafsari, Haidar S. and Chaudhuri, K. Ray and Mahlstedt,
Picabo and Sachse, Lena and Steffen, Julia K. and
Petry-Schmelzer, Jan Niklas and Dembek, Till A. and Reker,
Paul and Barbe, Michael and Visser-Vandewalle, Veerle and
Fink, Gereon R. and Timmermann, Lars},
title = {{B}eneficial effects of bilateral subthalamic stimulation
on alexithymia in {P}arkinson's disease},
journal = {European journal of neurology},
volume = {26},
number = {2},
issn = {1351-5101},
address = {Oxford},
publisher = {Blackwell Science91133},
reportid = {FZJ-2018-04895},
pages = {222-e17},
year = {2019},
abstract = {Background and purposeSubthalamic nucleus (STN) deep brain
stimulation (DBS) improves quality of life (QoL) and motor
and non‐motor symptoms in advanced Parkinson's disease
(PD). However, its effect on alexithymia and its
relationship to other neuropsychiatric symptoms and QoL in
PD is unclear.MethodsIn this prospective, observational
study of 39 patients with PD undergoing STN‐DBS, we
examined the Parkinson's Disease Questionnaire‐8
(PDQ‐8), 20‐item Toronto Alexithymia Scale (TAS‐20),
Hospital Anxiety and Depression Scale (HADS), Self‐Report
Manic Inventory (SRMI), Apathy Evaluation Scale (AES),
Unified Parkinson's Disease Rating Scale (UPDRS) activities
of daily living, UPDRS motor examination and UPDRS
complications (UPDRS‐II/‐III/‐IV) and
levodopa‐equivalent daily dose (LEDD) pre‐operatively
and at 5‐month follow‐up. Outcome changes were tested
with Wilcoxon signed‐rank or paired t‐test when
parametric tests were applicable and corrected for multiple
comparisons. The relationship between outcome changes was
explored with bivariate correlations. Additionally, partial
correlations between PDQ‐8 and TAS‐20 were computed
controlling for HADS, SRMI and AES change scores. Predictor
analyses for PDQ‐8 improvement were calculated for all
baseline parameters.ResultsThe baseline prevalence of
alexithymia was $17.9\%.$ We observed significant beneficial
effects of STN‐DBS on PDQ‐8, TAS‐20, HADS, UPDRS‐II,
‐III and ‐IV scores and significant LEDD reduction. The
correlation between TAS‐20 and PDQ‐8 improvements
remained significant after controlling for all other
aforementioned outcomes. Predictor analyses for PDQ‐8
improvement were significant for PDQ‐8 and
TAS‐20.ConclusionsThis is the first report of beneficial
effects of STN‐DBS on alexithymia. Alexithymia was
significantly associated with QoL outcome independent of
anxiety, depression, mania and apathy. Our study highlights
the importance of alexithymia for holistic assessments of
DBS outcomes.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30107062},
UT = {WOS:000455803800006},
doi = {10.1111/ene.13773},
url = {https://juser.fz-juelich.de/record/851195},
}